Posts tagged BioLight Life Sciences
BioLight posts positive latanoprost insert data

BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for a 12-week period, with a favorable safety profile.

Read More
BioLight TeaRx to be used in DES trial

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) announced that one of its subsidiaries, DiagnosTear, has signed a services agreement with a pharmaceuticals company to provide analysis services with its TeaRx multi-parameter diagnostic assays for use in an clinical trial for dry eye syndrome (DES).

Read More
BioLight’s CellDetect posts positive results in prostate cancer

BioLight Life Sciences (TASE:BOLT) reported promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology.

The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.

Read More
BioLight expands portfolio with eye drops for DES

BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications.

The product was in-licensed from Fischer Pharmaceuticals and RAMOT, the technology transfer arm of the Tel Aviv University.

Read More